Livzon Pharma Announces Updated Board Structure and Committee Line-up

Bulletin Express05-29

Livzon Pharmaceutical Group Inc. (Livzon Pharma) released an announcement dated 29 May 2026 confirming the latest composition of its Board of Directors and five specialist committees—Audit, Remuneration and Assessment, Nomination, Strategy, and Environmental, Social & Governance (ESG).

Board composition • Executive Directors: President Liu Daping; Vice-Chairman Tang Yanggang. • Non-executive Directors: Chairman Zhu Baoguo; Lin Nanqi; Qiu Qingfeng. • Employee Representative Director: Ran Yongmei. • Independent Non-executive Directors (INEDs): Luo Huiyuan; Cui Lijie; Wang Zhiyao; Kang Li.

Committee highlights • Five Board committees remain in place, each covering key areas of governance, strategy, and oversight. • Chairman Zhu Baoguo holds chairmanships on two committees, underscoring his central role in board-level decision-making. • INED Kang Li chairs one committee and serves as a member on two others, reflecting the regulatory emphasis on independent oversight. • Vice-Chairman Tang Yanggang sits on four committees, indicating deep involvement in both operational and strategic matters. • INEDs Luo Huiyuan and Cui Lijie each hold a mix of chair and member positions, supporting board independence across critical functions. • INED Wang Zhiyao and Employee Representative Director Ran Yongmei serve as members on selected committees, providing additional expertise and employee perspectives.

The disclosure aligns with Hong Kong Listing Rules, offering investors and stakeholders full visibility into the governance structure guiding Livzon Pharma’s strategic, financial, and ESG initiatives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122253162?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122253162","market":"hk","top_or_hot":-1,"title":"Livzon Pharma Announces Updated Board Structure and Committee Line-up","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. (Livzon Pharma) released an announcement dated 29 May 2026 confirming the latest composition of its Board of Directors and five specialist committees—Audit, Remuneration and Assessment, Nomination, Strategy, and Environmental, Social & Governance (ESG).</p>\n<p>Board composition  \n• Executive Directors: President Liu Daping; Vice-Chairman Tang Yanggang.  \n• Non-executive Directors: Chairman Zhu Baoguo; Lin Nanqi; Qiu Qingfeng.  \n• Employee Representative Director: Ran Yongmei.  \n• Independent Non-executive Directors (INEDs): Luo Huiyuan; Cui Lijie; Wang Zhiyao; Kang Li.</p>\n<p>Committee highlights  \n• Five Board committees remain in place, each covering key areas of governance, strategy, and oversight.  \n• Chairman Zhu Baoguo holds chairmanships on two committees, underscoring his central role in board-level decision-making.  \n• INED Kang Li chairs one committee and serves as a member on two others, reflecting the regulatory emphasis on independent oversight.  \n• Vice-Chairman Tang Yanggang sits on four committees, indicating deep involvement in both operational and strategic matters.  \n• INEDs Luo Huiyuan and Cui Lijie each hold a mix of chair and member positions, supporting board independence across critical functions.  \n• INED Wang Zhiyao and Employee Representative Director Ran Yongmei serve as members on selected committees, providing additional expertise and employee perspectives.</p>\n<p>The disclosure aligns with Hong Kong Listing Rules, offering investors and stakeholders full visibility into the governance structure guiding Livzon Pharma’s strategic, financial, and ESG initiatives.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharma Announces Updated Board Structure and Committee Line-up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharma Announces Updated Board Structure and Committee Line-up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-29 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. (Livzon Pharma) released an announcement dated 29 May 2026 confirming the latest composition of its Board of Directors and five specialist committees—Audit, Remuneration and Assessment, Nomination, Strategy, and Environmental, Social & Governance (ESG).</p>\n<p>Board composition  \n• Executive Directors: President Liu Daping; Vice-Chairman Tang Yanggang.  \n• Non-executive Directors: Chairman Zhu Baoguo; Lin Nanqi; Qiu Qingfeng.  \n• Employee Representative Director: Ran Yongmei.  \n• Independent Non-executive Directors (INEDs): Luo Huiyuan; Cui Lijie; Wang Zhiyao; Kang Li.</p>\n<p>Committee highlights  \n• Five Board committees remain in place, each covering key areas of governance, strategy, and oversight.  \n• Chairman Zhu Baoguo holds chairmanships on two committees, underscoring his central role in board-level decision-making.  \n• INED Kang Li chairs one committee and serves as a member on two others, reflecting the regulatory emphasis on independent oversight.  \n• Vice-Chairman Tang Yanggang sits on four committees, indicating deep involvement in both operational and strategic matters.  \n• INEDs Luo Huiyuan and Cui Lijie each hold a mix of chair and member positions, supporting board independence across critical functions.  \n• INED Wang Zhiyao and Employee Representative Director Ran Yongmei serve as members on selected committees, providing additional expertise and employee perspectives.</p>\n<p>The disclosure aligns with Hong Kong Listing Rules, offering investors and stakeholders full visibility into the governance structure guiding Livzon Pharma’s strategic, financial, and ESG initiatives.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"","article_id":"1122253162","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122253162","pubTimestamp":1780058613,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. (Livzon Pharma) released an announcement dated 29 May 2026 confirming the latest composition of its Board of Directors and five specialist committees—Audit,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药宣布更新董事会架构及委员会阵容","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. (Livzon Pharma) released an announcement dated 29 May 2026 confirming the latest composition of its Board of Directors and five specialist committees—Audit, Remuneration and Assessment, Nomination, Strategy, and Environmental, Social & Governance (ESG).\nBoard composition  \n• Executive Directors: President Liu Daping; Vice-Chairman Tang Yanggang.  \n• Non-executive Directors: Chairman Zhu Baoguo; Lin Nanqi; Qiu Qingfeng.  \n• Employee Representative Director: Ran Yongmei.  \n• Independent Non-executive Directors (INEDs): Luo Huiyuan; Cui Lijie; Wang Zhiyao; Kang Li.\nCommittee highlights  \n• Five Board committees remain in place, each covering key areas of governance, strategy, and oversight.  \n• Chairman Zhu Baoguo holds chairmanships on two committees, underscoring his central role in board-level decision-making.  \n• INED Kang Li chairs one committee and serves as a member on two others, reflecting the regulatory emphasis on independent oversight.  \n• Vice-Chairman Tang Yanggang sits on four committees, indicating deep involvement in both operational and strategic matters.  \n• INEDs Luo Huiyuan and Cui Lijie each hold a mix of chair and member positions, supporting board independence across critical functions.  \n• INED Wang Zhiyao and Employee Representative Director Ran Yongmei serve as members on selected committees, providing additional expertise and employee perspectives.\nThe disclosure aligns with Hong Kong Listing Rules, offering investors and stakeholders full visibility into the governance structure guiding Livzon Pharma’s strategic, financial, and ESG initiatives.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122253162","isCrawlerRequest":true}